| Wissenschaftl. Titel | A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% |
| Erkrankung |
Thorax:
Nicht-kleinzelliges Lungenkarzinom:
Erstlinie
|
| Molekularer Marker |
PD-L1 > 50% |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (MZ) |
erstellt 24.10.2024 Data entry III CCP
geändert 05.12.2024 Data entry IX CCP